Eosinophilic Esophagitis (EoE): Opportunity Assessment and Forecast - Update
Description
Eosinophilic Esophagitis (EoE): Opportunity Assessment and Forecast - Update
Summary
This report covers the US and provides an Excel-based forecast model for the EoE market through 2030.
The current standard of care for EoE includes proton pump inhibitors, swallowed topical corticosteroids, and dietary elimination approaches. While biologics such as dupilumab have introduced new options, many patients experience partial response, relapse upon treatment discontinuation, or challenges with long-term adherence to dietary regimens.
The US EoE market is expected to grow to $1.2B, driven by the introduction of biologics and the late-stage pipeline.
Market growth will be underpinned by novel biologics and advanced topical corticosteroid formulations, alongside broader adoption of pediatric and mild-to-moderate patient treatment. Companies demonstrating durable efficacy and patient-centric outcomes are expected to capture share in this evolving, underpenetrated market.
Scope
Summary
This report covers the US and provides an Excel-based forecast model for the EoE market through 2030.
The current standard of care for EoE includes proton pump inhibitors, swallowed topical corticosteroids, and dietary elimination approaches. While biologics such as dupilumab have introduced new options, many patients experience partial response, relapse upon treatment discontinuation, or challenges with long-term adherence to dietary regimens.
The US EoE market is expected to grow to $1.2B, driven by the introduction of biologics and the late-stage pipeline.
Market growth will be underpinned by novel biologics and advanced topical corticosteroid formulations, alongside broader adoption of pediatric and mild-to-moderate patient treatment. Companies demonstrating durable efficacy and patient-centric outcomes are expected to capture share in this evolving, underpenetrated market.
Scope
- Overview of EoE, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized EoE therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the EoE market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for EoE. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the US EoE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the US EoE therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EoE therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
66 Pages
- Abbreviations
- Related Reports
- Summary of Updates
- Executive Summary
- Disease Overview
- Overview of Eosinophilic Esophagitis
- Etiology of EoE
- Pathophysiology of EoE
- Classification of EoE
- Diagnostic Paradigm
- Diagnosis: KOL Insights
- EoE SWOT Analysis
- Epidemiology
- Lifetime Diagnosed Prevalent Cases of EoE, All Ages, Both Sexes, 2020-30
- Sources and Methodology for Lifetime Diagnosed Prevalent Cases of EoE
- Sources and Methodology - Lifetime Diagnosed Prevalent Cases of EoE
- Current Treatment Options
- Treatment Paradigm (1/2)
- Treatment Paradigm (2/2)
- Current Treatments for EoE
- Product Profile: Proton Pump Inhibitors (PPI)
- Product Profile: Glucocorticoid Receptor Agonist (GRA)
- Product Profile: Dupixent (dupilumab)
- Product Profile: Eohilia (budesonide)
- Unmet Needs and Opportunities
- Unmet Needs in EoE
- Non-invasive Monitoring Tools
- Durable Disease Control and Efficacy
- Access and Affordability
- R&D Strategies
- Trends in Clinical Trial Design in EoE (1/2)
- Trends in Clinical Trial Design in EoE (2/2)
- Trends in Deal-Making in EoE
- Top 10 Deals for EoE
- Pipeline Assessment
- EoE Pipeline Overview
- Late-Stage Pipeline Agents for EoE
- Late-Stage Pipeline Agents for HS (2/2)
- Product Profile: Ellodi’s APT-1011 (fluticasone)
- Product Profile: Amgen’s Tezspire (tezepelumab)
- Clinical Trials in the EoE Space
- Market Outlook
- EoE Market Forecast (1/2)
- EoE Market Forecast (2/2)
- US Market Drivers and Barriers
- Appendix
- Primary Research: KOL Information
- Bibliography
- About the Authors
- Contact Us
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
